Philips and MIT IMES develop enhanced critical care data set to give researchers and educators access to advance clinical understanding and AI in healthcare
April 18, 2023 10:00 ET
|
Royal Philips
April 18, 2023 Latest clinical data set of 200,000 patients from over 200 hospitals, includes pandemic data for a broader and dependable foundation for machine learning Amsterdam, the Netherlands...
GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses
April 17, 2023 09:00 ET
|
GeoVax, Inc.
Expanded Rights Include Development of GEO-CM04S1 Against Mpox (Monkeypox) and Smallpox ATLANTA, GA, April 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a...
Blood Testing Market to Reach USD 218.2 Bn by 2032 Growing at a 9.6% CAGR | TMR Study
April 14, 2023 12:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, April 14, 2023 (GLOBE NEWSWIRE) -- The blood testing market was valued at USD 80.2 Bn in 2021 and the global market is anticipated to reach USD 218.2 Bn....
AIM ImmunoTech Appoints Preeminent Biotechnology Pioneer, W. Neal Burnette, Ph.D., as Chairman of its Scientific Advisory Board (SAB)
April 12, 2023 08:35 ET
|
AIM ImmunoTech Inc.
Company’s SAB is comprised of well-established leaders with expertise across biomedical research, academia, and pharmaceutical industry OCALA, Fla., April 12, 2023 (GLOBE NEWSWIRE) -- AIM...
Dyadic Announces Expanded Licensing Agreement to Develop and Commercialize Vaccines and Biologics for African Continent
April 12, 2023 08:00 ET
|
Dyadic International, Inc.
JUPITER, Fla., April 12, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building...
InflaRx Receives FDA Emergency Use Authorization for Gohibic (vilobelimab) for Treatment of Critically Ill COVID-19 Patients
April 04, 2023 14:55 ET
|
InflaRx N.V.
Vilobelimab is the first authorized drug to control complement factor C5a, a protein that plays an important and often harmful role in the body's immune responseFDA granted EUA based on Phase III...
AIM ImmunoTech Announces Central IRB Approval of Phase 2 Study Protocol Evaluating Ampligen® for the Treatment of Post-COVID Conditions
April 04, 2023 08:45 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., April 04, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
Veru Announces Preclinical Results from Expanded Sabizabulin Program into Influenza-Induced Severe Acute Respiratory Distress Syndrome and Provides Update on COVID-19 Program
April 04, 2023 08:30 ET
|
Veru Inc.
In the final report, sabizabulin significantly reduced key cytokines involved in Acute Respiratory Distress Syndrome (ARDS) in H1N1 influenza pulmonary inflammation murine ARDS model Positive...
AIM ImmunoTech Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
April 03, 2023 06:30 ET
|
AIM ImmunoTech Inc.
– Company continues to execute across development pipeline of high-value indications with 12 active clinical programs – Well-positioned to achieve multiple near-term, value-driving milestones –...
GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Target Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – TGT
April 01, 2023 18:25 ET
|
The Rosen Law Firm PA
NEW YORK, April 01, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of Target...